Abbott(ABT) ZACKS·2024-10-29 13:11Company Overview - Abbott Laboratories, Inc. (ABT) has launched a pioneering clinical trial named TEAM-HF aimed at improving outcomes for patients with worsening heart failure, enrolling 850 patients across 75 sites globally to measure pulmonary artery pressures using the CardioMEMS HF System [1][5][6] Clinical Trial Details - The TEAM-HF trial seeks to identify advanced heart failure patients at high risk of mortality who may benefit from the HeartMate 3 left ventricular assist device (LVAD) earlier in their disease progression [2][6] - The trial will utilize data from the CardioMEMS sensor, which monitors pulmonary artery pressure changes over time, to assess the impact of earlier interventions [5][6] - Patients will be randomized to receive either the HeartMate 3 LVAD implant or continue with their existing heart failure medications, with follow-up evaluations at two years and long-term follow-up through five years [6][7] Financial Performance - Abbott has a market capitalization of 114.07 [3] - Over the past three months, Abbott shares have increased by 8.3%, slightly outperforming the industry growth of 8.1% [9] Industry Prospects - The global cardiovascular devices market was valued at $49.18 billion in 2023 and is projected to grow at a compound annual growth rate of 8.3% through 2030, driven by technological advancements and rising demand for minimally invasive procedures [8]